“…Similar problems are evident for most herbs used in the context of TCM [8,12,15,17,62,63,64,65,66,67,119,120,121,122,123,124,181,185,229,230,231,232,233], which were discussed by the Chinese FDA, presenting details of the current status and future perspectives of the pharmacovigilance practice and risk control of TCM drugs in China [12]. …”